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Abstract
This study presents a new multimodal imaging approach that includes high-frequency ultrasound, fluorescence intensity,
confocal, and spectral imaging to improve the preclinical evaluation of new therapeutics in vivo. Here we use this approach
to assess in vivo the therapeutic efficacy of the novel chemotherapy construct, HerDox during and after treatment. HerDox
is comprised of doxorubicin non-covalently assembled in a viral-like particle targeted to HER2+ tumor cells, causing tumor
cell death at over 10-fold lower dose compared to the untargeted drug, while sparing the heart. Whereas our initial proof-
of-principle studies on HerDox used tumor growth/shrinkage rates as a measure of therapeutic efficacy, here we show that
multimodal imaging deployed during and after treatment can supplement traditional modes of tumor monitoring to further
characterize the particle in tissues of treated mice. Specifically, we show here that tumor cell apoptosis elicited by HerDox
can be monitored in vivo during treatment using high frequency ultrasound imaging, while in situ confocal imaging of
excised tumors shows that HerDox indeed penetrated tumor tissue and can be detected at the subcellular level, including in
the nucleus, via Dox fluorescence. In addition, ratiometric spectral imaging of the same tumor tissue enables quantitative
discrimination of HerDox fluorescence from autofluorescence in situ. In contrast to standard approaches of preclinical
assessment, this new method provides multiple/complementary information that may shorten the time required for initial
evaluation of in vivo efficacy, thus potentially reducing the time and cost for translating new drug molecules into the clinic.
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Introduction
Different types of radiation, including light, radio-waves,
ultrasound, x-rays, and gamma rays, have all been utilized to
image the structure and function of tissues of interest inside a living
object. Each imaging modality offers different spatial and temporal
resolutions as well as different sensitivities in measurement of
morphological or functional properties of tissues [1,2]. Therefore,
the simultaneous use of different imaging modalities should
combine the strengths while reducing the shortcomings inherent
to each individual modality, thus allowing enhanced diagnosis,
therapeutic monitoring, and improved preclinical research.
Because of the aforementioned advantages, noninvasive multi-
modal imaging based on optical, ultrasound, magnetic resonance
imaging (MRI), computerized-tomography (CT), single-photon
emission computed tomography (SPECT), and positron emission
tomography (PET) is now not only becoming standard practice in
the clinic, but also a rapidly emerging technique for a variety of in
vivo preclinical studies, from molecular pharmacology to stem cell
research [1,3–12].
To date, much effort has been focused on the development of
non-invasive multimodal imaging approaches, aimed at visualizing
diseased lesions and monitoring stem cell migration. For instance,
tumor angiogenesis has been detected and monitored using
intravital confocal, MRI, and optical imaging simultaneously with
novel multimodal quantum dots [10], whereas breast cancer
micro-calcifications have been detected using dual modality
SPECT/NIR fluorescence imaging [13]. In addition, PET and
bioluminescence imaging have been simultaneously employed to
noninvasively monitor implanted neural progenitor cells and their
migrations [7,14]. Moreover, multimodal imaging can enable
improved identification of new drug candidates by detecting
enhanced efficiency, thus reducing cost and time for drug
development [15,16].
We have previously developed the viral capsid-derived fusion
protein, HerPBK10, which targets noncovalently attached thera-
peutic molecules to human epidermal growth factor receptor 2-
positive (HER2+) cells, including breast, ovarian, and glioma
cancer cells, and mediates penetration into the tumor cells,
resulting in tumor-targeted toxicity [17–23]. Our recent studies
have shown that the tumor-targeted gallium corrole, HerGa
(which results from the spontaneous, non-covalent assembly of the
sulfonated gallium corrole, S2Ga, and HerPBK10), exhibits
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intense fluorescence and cytotoxicity to HER2+ MDA-MB-435
cancer cells, thus enabling both tumor detection and elimination
[17–19]. In those studies, we for the first time employed a
multimode optical imaging system, specifically using fluorescence
intensity, spectral, lifetime, and two-photon excited fluorescence
imaging modes, to assess HerGa in vivo. This multimode optical
imaging in vivo allowed us to monitor the kinetics of the drug
molecule accumulation in small animals as well as specifically and
quantitatively characterize the in vivo micro-environment sur-
rounding the drug with micro- to macro-scopic resolution [24,25].
More recently, we have developed another novel chemotherapy
particle, HerDox, which is a non-covalent assembly of doxorubicin
with HerPBK10. That study showed that HerDox allows
doxorubicin potency to remain unaltered during assembly,
transport, and release into target cells while enabling lower drug
dose for tumor killing, thus improving the safety of doxorubicin
over standard untargeted treatment that is used in the clinic [26].
As the carrier protein used in both HerGa and HerDox can be
modified to target other tumor types, we have recently explored
the possibility of whether preclinical evaluation of such targeted
particles can be expedited through new combination of multiple
imaging modalities.
In the present study, we for the first time combined four
imaging modalities (Fig. 1), including high-frequency ultrasound,
fluorescence intensity, confocal, and ratiometric spectral imaging
[25], in order to characterize our tumor-targeted doxorubicin
nanoparticles in vivo and ex vivo. High-frequency ultrasound
imaging provides tissue microanatomy with better spatial resolu-
tion than standard ultrasound imaging, thus enabling one to
monitor structural changes of the regions of interest, including cell
apoptosis in vivo. In contrast, fluorescence intensity imaging is
suited for continuous tracking of movements and concentrations of
labeled molecules in vivo and ex vivo, based on the spatial
distribution of intensity, thus monitoring the effects of drug
candidates on the target pathology. Ratiometric spectral imaging
provides quantitative spectral signatures at every pixel of an image,
allowing one to discriminate between the background (autofluo-
rescence) and fluorescence of interest more quantitatively and
specifically [26]. Confocal microscopy provides better depth-
selectivity imaging than standard fluorescence microscopy, thus
identifying the localization of molecules in tissues with high
resolution [24]. The combination of these imaging modes
compared to using a single imaging mode alone offers multiple/
complementary information, thus enabling better in vivo charac-
terization of nanoparticles such as the ones tested here. In this
study, tumor response to HerDox treatment was quantitatively
monitored in vivo using high-frequency ultrasound imaging, and
cell death was verified using confocal fluorescence imaging of
immunostained tumor sections extracted from HerDox-treated
and untreated mice. In addition, we verified the tumor-preferential
biodistribution of HerDox using fluorescence intensity imaging,
and analyzed specific accumulation and localization in tumors in
situ using high-resolution confocal and spectral imaging and
analysis. These results demonstrate that the multimodal imaging
approach presented here is suited for the assessment of new
chemotherapy nanoparticles as a novel alternative to standard,
single-mode imaging.
Materials and Methods
Ethics Statement
All in vivo and euthanasia procedures in this study were carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the Cedars-
Sinai Medical Center Institutional Animal Care and Use
Committee (IACUC) (Protocol Number: 2794). All efforts were
made to minimize suffering.
Materials
The MDA-MB-435 human HER2+ tumor cell line was
obtained from the National Cancer Institute, and maintained in
DMEM, 10% fetal bovine serum under 5% CO2. Doxorubicin-
HCI was purchased from Sigma-Aldrich. HBS, HEPES-buffered
saline (20 mM HEPES, pH 7.5; 150 mM NaCl); PBS, phosphate-
buffered saline. For TUNEL staining of tumor sections, an in situ
cell death detection kit was purchased from Roche Applied
Science (IN, USA).
Animals
Female immunodeficient (nu/nu) mice (6–8 weeks; Charles
River Laboratories International, Wilmington, MA, USA) re-
ceived subcutaneous bilateral flank injections of 16107 MDA-MB-
435 cells/injection to create a xenograft tumor model, and tumor
growth monitored by measuring tumor volume via calipers.
Treatments were initiated after tumors reached ,200–300 mm3.
HerDox assembly
The viral capsid-derived fusion protein, HerPBK10, was
assembled with doxorubicin following established procedures
[26]. Briefly, complementary oligonucleotide duplexes were
incubated with Dox at 1:10 molar ratio of DNA:Dox at room
temperature (RT) for 30 minutes, followed by incubation with
HerPBK10 at 6:1 molar ratio of HerPBK10:DNA-Dox in HBS,
followed by ultrafiltration using 50 k MW cutoff (mwco) filter
membranes to isolate HerDox from incompletely assembled
components. The Dox concentration in HerDox was determined
by extrapolating the measured absorbance at 480 nm or
fluorescence at 590 nm (Ex: 480 nm) against a Dox absorbance
or fluorescence calibration curve (SpctraMax, Molecular Devices,
USA). HerDox dose is based on the concentration of Dox in
HerDox.
Figure 1. Multimodality imaging for preclinical assessment of
nanoparticles and information provided by each modality.
doi:10.1371/journal.pone.0034463.g001
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HerDox and Dox tail-vein administration
,200 ml of HerDox at 1 mM (0.004 mg/kg) and ,200 ml of
HerDox at 10 mM (0.04 mg/kg), in which the injection volume
was dependent on the weight of mice (28–30 g), were injected
daily into mice (HerDox: n = 3, Dox: n = 3, and untreated: n= 3)
through the tail-vein using 3/10cc insulin syringe (Needle size: 29G
K0) for six sequential days. Mice were anesthetized before tail-vein
injections following IACUC-approved procedures.
High-frequency ultrasound imaging
A custom-built ultrasound bio-microscope (UBM) was utilized
for high-frequency ultrasound imaging. A 40 megahertz (MHz)
LiNbO3 light-weight single-element ultrasound transducer, with a
fixed focal distance at 6 mm and bandwidth of 75%, was used to
scan the tumor regions of treated mice [27]. The transmission
signal emitted from the transducer was a three cycle sine burst of
50 MHz with 80 V peak-to-peak voltage. Importantly, the
transmission condition was maintained during the evaluation of
HerDox efficacy for the tumor treatment.
Ultrasound images of tumor regions in vivo were obtained before
drug (HerDox and Dox) administration, after the third daily
intravenous (IV) administration, and 24 h after the last (sixth) daily
IV administration to the tumor-bearing mice (three mice, or six
tumors, per group) respectively. Here, the dose of Dox at
0.04 mg/kg/day was chosen as a positive control since this dose
of untargeted Dox exhibits similar efficacy on tumor treatment to
the dose of HerDox at 0.004 mg/kg/day [26]. The transducer
covered by a TegadermTM transparent dressing (3 M, St. Paul,
MN) was coupled to the skin after an ultrasonic gel was generously
spread on the surface of the transducer for the in vivo imaging.
After ultrasound signals were transmitted to the tumor sites,
ultrasound echo signals from the sites were detected by the
transducer and post-processed using a program we developed
(Matlab R2010b, Mathworks) to construct ultrasound images.
During each measurement at the indicated time points, an almost
identical tumor site of each mouse was placed at the focal distance
of the transducer. In addition, the tumors were harvested from the
mice, and then imaged in order to examine the echo intensity
changes in the ex vivo tumors (4 tumors per group) after the drug
treatment.
For the quantitative analysis, we calculated the mean intensities
of ultrasound echo signal from tumor regions in the images
obtained at indicated time-points in vivo and ex vivo and compared
the mean intensities of tumors before and after the HerDox and
Dox treatment.
Fluorescence intensity imaging ex vivo
Fluorescence intensity imaging of tumors and specific organs
(including the liver, kidney, spleen, heart, and skeletal muscle) was
performed by harvesting tissues from euthanized mice 24 h after
the mice received daily tail vein injections of 0.004 mg/kg
HerDox for 6 consecutive days. A multimode optical imaging
system that we previously developed [24] was used here for the
fluorescence intensity imaging ex vivo. For excitation of HerDox,
532 nm laser light (CrystaLaser, up to ,0.5 W), which provides
better tissue penetration than 488 nm laser light [28], was
delivered onto specimens through several mirrors and diffusers,
and then emission light from the specimens was filtered through an
emission filter (590630 nm), and recorded in a high-sensitivity
cooled CCD camera (PIXIS 400, Princeton Instruments, quantum
efficiency at 590 nm: ,95%). After the fluorescence images were
acquired, background subtraction of the images was performed
using ImageJ to reduce artifacts resulting from the laser beam
profile. It is noted that although the light wavelength utilized here
was not perfectly matched with the typical maximum absorption
wavelengths (,480–490 nm) for excitation of Dox, light at
532 nm is still capable of considerable (fraction with respect to
the maximum absorbance: 0.86) Dox excitation in tissues [26].
In situ confocal/spectral imaging and analysis
The in situ confocal imaging was performed using a Leica SPE
confocal microscope with a 488 nm laser light delivered onto the
tumors for excitation of HerDox, while the fluorescence from the
tumors was collected by a 406 ACS oil objective. Fluorescence
within 550–600 nm was selected by an acousto-optic tunable filter
(AOTF) and recorded in a photomultiplier tube incorporated in
the microscope. A total of 18 confocal fluorescence images of
HerDox-treated, Dox-treated, and untreated tumors were ac-
quired at sequential z-depths within 36 mm with a step size of
2 mm respectively. A maximum intensity z-projection of the
images was performed, and then mean fluorescence intensities of
the images were measured using ImageJ software.
Ratiometric spectral imaging and analysis with spectral
unmixing
For ratiometric spectral imaging and analysis, which offers a
more quantitative analysis than standard spectral imaging in
chemotherapy assessment [25], 15 images of the HerDox-treated
and untreated tumors at a specified depth were acquired within
the spectral range of 510–650 nm, with a step size of 10 nm, while
HerDox was excited by 488 nm light using a Leica SPE confocal
microscope. Reference spectral signatures were created through
combination of different ratios of a pure doxorubicin and auto-
fluorescence spectral signature. Here it is important to note that
there is no significant difference between the spectral signatures of
HerDox and Dox fluorescence to have any significant effects on
separating doxorubicin from autofluorescence [26]. Therefore, we
utilized the spectral signature of free doxorubicin to perform the
ratiometric spectral imaging and analysis. While the pure spectral
signature of doxorubicin was acquired from an image cube
(spectral range: 510–650 nm, a step size: 10 nm), obtained by
spectral imaging of 100 mM doxorubicin solution using the Leica
SPE confocal microscope, the autofluorescence spectral signature
was acquired from an image cube (spectral range: 510–650 nm, a
step size: 10 nm) obtained by spectral imaging of untreated tumors
[25]. Here four reference spectral signatures (pure autofluores-
cence, 0.1?doxorubin+0.9?autofluorescence, 0.2? doxorubici-
n+0.8?autofluorescence, 0.3?doxorubin+0.7?autofluorescence)
were generated for the classification using a program we
previously developed [25], as the reference spectral signatures
with higher ratio of doxorubicin more than 0.4 relative to
autofluorescence did not have any significant effects on spectral
classification (equation for generating the mixed spectral signa-
tures: S= a16A+a26H, where S is the composite spectral signature,
A and H are the spectral signatures of autofluorescence and Dox
fluorescence respectively, and an is the relative contribution of the
signals). The spectral classification of the images as defined by the
reference spectral signatures was performed based on Euclidean
distance measure using a program we previously developed [25].
Furthermore, linear spectral unmixing of those images was
performed by using a spectral unmixing program (plug-in in
ImageJ we developed), for comparison to the ratiometric spectral
imaging and analysis.
H&E and TUNEL imaging
For TUNEL staining of the sections of tumors extracted from
the mice treated with different drug molecules, the unstained
Multimodality Imaging for HerDox Assessment
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sections were dewaxed and hydrated by the following procedures;
1) sections were incubated in dry oven 60 deg for 1 hour; 2)
submerged in xylenes for 4 min, 5 times; 3) hydrated by
submerging in 100%, 95%, 90%, 80%, 70% ethanol for 3 min,
2 times each; 4) submerged in 100% water. After the dewax and
hydration of the sections, epitope retrieval of the sections was
performed with Proteinase K (20 ug/ml in 10 mM Tris pH 7.8),
and then followed by TUNEL staining using the in situ cell death
detection kit (following the manufacturer’s procedures; Roche
applied science, Indianapolis, IN, USA) after the sections were
rinsed with PBS. After TUNEL staining of the tumor sections,
confocal fluorescence imaging of the sections was performed using
a Leica confocal SPE microscope (206, ex: 488 nm, and em:
530 nm). In addition, the hematoxilin and eosin (H&E) sections,
prepared by the Pathology Service at the Cedars-Sinai Medical
Center, were imaged using an Olympus microscope (IX71)
incorporating a CCD camera (QImaging, RETIGA EXI) and a
liquid crystal RGB filter (CRI).
Statistical Analysis
Ultrasound echo signal increase of tumor regions after HerDox
and Dox injection was evaluated for each group by the ultrasound
echo signal of the tumor regions before drug injection as a
reference in vivo. In addition, ultrasound echo signal of harvested
tumors of mice receiving HerDox and Dox were compared to the
signal of harvested tumors of mice without treatment ex vivo. All
data are expressed as mean 6 standard deviation of indicated
sample sizes, and were analyzed by a two-sided paired t test, with
the level of significance set at P = 0.05.
Results
High-frequency ultrasound imaging detects and
monitors HerDox-mediated tumor cell death during
treatment in vivo
Our previous studies on the therapeutic efficacy of HerDox
entailed regular measurements of tumor growth during and after
treatment over several weeks of tumor monitoring [26]. Here we
examined the utility of ultrasound imaging for assessing whether
immediate effects of HerDox treatment could be detected in vivo
during treatment. Our previous study showed that 0.004 mg/kg
HerDox is as effective as 10-fold higher [0.04 mg/kg] untargeted
Dox on tumor ablation [26]. Therefore, these doses were chosen
for the present study. Tumor-bearing mice received daily
intravenous injections of HerDox (0.004 mg/kg/day) or Dox
(0.04 mg/kg/day) for up to six days while ultrasound imaging of
tumor regions was performed before drug administration, and
after the third and sixth days of drug administration. Both the
scattering area and intensity at tumor sites (indicated by arrows)
increased with both HerDox and Dox treatment frequency
[Fig. 2A and B, ultrasound images]. In contrast, the untreated
tumors do not exhibit any significant increases (p =,0.95)
(Fig. 2C). Quantification of scattering intensity (Fig. 2, graphs)
showed that the average intensity of the tumor increased
considerably after the third injection and increased nearly two-
fold higher over untreated tumors by the sixth injection (HerDox:
p =,0.0009, Dox: P=,0.0010). There were no significant
differences in the average intensity values of between HerDox-
treated and Dox-treated tumors after the sixth drug administration
(p = 0.6097), suggesting that 0.004 mg/kg HerDox and 0.04 mg/
kg Dox exhibit similar treatment efficacy on tumors.
In order to verify the in vivo results, we performed high-
frequency ultrasound imaging of tumors extracted from the same
mice receiving daily HerDox and Dox injections for 6 days. The ex
vivo imaging shows that the overall echo intensities of both HerDox
[Fig. 3B] (p = 0.002) and Dox [Fig. 3C] -treated tumors (p = 0.003)
are significantly higher than those of untreated -tumors [Fig. 3A].
Quantitatively, these intensities were nearly twice as high as those
of the untreated tumors. Finally, as the source of this increase in
echo intensity might be attributed to nuclear condensation and
fragmentation in apoptotic cells [29–32], we examined the
aforementioned tumors for apoptosis. After harvesting tumors
from the same mice treated with HerDox and Dox for 6 days and
the untreated mice, H&E stained and unstained sections of the
tumors were prepared for histochemical assessment. The TUNEL
images show that both HerDox and Dox treatments resulted in
apoptotic marker elevation over tumors from un–treated mice
(Fig. 4A). TUNEL fluorescence measurements of HerDox-treated
tumors significantly differed (p,0.01) from those of untreated
tumors (Fig. 4A, bar graph). In addition, greater nuclear shrinkage
and fragmentation (arrows) could be observed in the H&E images
of HerDox and Dox -treated tumors (Fig. 4B) than untreated
tumors.
Combining fluorescence intensity, in situ confocal, and
spectral imaging modalities enables quantitative
discrimination of HerDox fluorescence from
autofluorescence
To assess whether HerDox could be detected in treated tumors
at the cellular and subcellular level, and discriminate HerDox
fluorescence from autofluorescence, we introduced high-resolution
in situ confocal and ratiometric spectral imaging. The inherent
fluorescence of Dox has the potential to enable studies in its
biodistribution, depending on the dose of Dox and the sensitivity
of the imaging system. In our previous studies, fluorescence
intensity imaging allowed us to track the biodistribution of
HerDox and demonstrate that HerDox undergoes tumor-specific
targeting in vivo, in contrast to free, untargeted Dox [26]. In the
present study, tumors and tissues extracted from mice 24 h after
receiving daily i.v. injections of HerDox (0.004 mg/kg/day) for 6
consecutive days were examined by fluorescence intensity, in situ
confocal, and ratiometric spectral imaging. The fluorescence
intensities measured from tumors of HerDox-treated mice were
over 50% higher than those measured from the liver, kidney, and
skeletal muscle, while the heart and spleen exhibited no detectable
fluorescence [Fig. 5A, left]. In situ confocal imaging [Fig. 5A,
right] showed that the fluorescence intensity of tumor cells from
HerDox-treated mice [Fig. 5A, right] was significantly higher than
that of tumor cells from untreated mice [Fig. 5B]. Moreover, Dox
fluorescence could be detected in the nuclei of HerDox-treated
tumor cells, [Fig. 5A right, arrows], but not in the nuclei of
untreated tumor cells [Fig. 5B]. In contrast, unlike in Fig. 5(A), we
could not determine whether Dox fluorescence could be detected
in the nuclei of Dox treated tumor cells. Here quantitative analysis
(Fig. 5C) shows that the average fluorescence intensity of HerDox
treated tumors is almost twice that of untreated tumors (p,0.01)
as well as higher than that of Dox-treated tumors (p,0.01). Here,
the standard deviation of fluorescence intensity for HerDox
treated tumors is somewhat higher than others since there is
considerable difference in fluorescence intensities between Her-
Dox and non-HerDox regions, as shown in Fig. 5A and 5B. Thus,
these results verify that the combination of these imaging
modalities allows us to quantitatively assess tumor-accumulation
of HerDox at cellular and sub-cellular levels in detail.
Ratiometric spectral imaging and analysis allowed discrimina-
tion between doxorubicin fluorescence of HerDox and autofluo-
rescence in the same tumor areas. The reference spectral
Multimodality Imaging for HerDox Assessment
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signatures [Fig. 6A, left] generated through the ratiometric
method previously described (see Methods) show the relative
HerDox contributions on the spectral signature of autofluores-
cence. The reference spectral signatures containing doxorubicin
spectra with different ratios exhibit a peak at ,590 nm, which is
the typical maximum emission wavelength for HerDox, whereas
the spectral signature of the autofluorescence exhibits no such
peak at that wavelength [Fig. 6A, left]. The spectral classification
images generated from these signatures [Fig. 6A, middle and right]
clearly distinguished HerDox fluorescence from autofluorescence
quantitatively and specifically, in spite of their strong spectral
overlap. In particular, the classified image [Fig. 6A, middle]
generated by four reference spectral signatures (cyan:
0.3?Dox+0.7?Autofl., red: 0.2?Dox+0.8?Autofl., blue:
0.1?Dox+0.9?Autofl., Green: Autofl.) allowed a greater degree of
quantification than the classified image [Fig. 6A, right] generated
by two reference spectral signatures (red: 0.2?Dox+0.8?Autofl. and
Green: Autofl.) [25]. Moreover, the spectral unmixed image
Figure 2. High-frequency ultrasound imaging of tumor regions in mice receiving (A) 0.004 mg/kg/day HerDox or (B) 0.04 mg/kg/
day Dox, by i.v. delivery and in (C) untreated mice: Ultrasound images of tumor regions were obtained after the indicated drug
injection (before drug injection, after the third daily drug injection, and after the sixth daily drug injection) while mice received
daily i.v. injections of the indicated drugs for six sequential days. Graphs (right-panel) depict average echo intensities of tumor regions (0,
before drug injection; 3, immediately after the third daily drug injection; 6, 24 h after the sixth daily drug injection). *: p,0.01, +: p =,0.6097, and
2 : p =,0.95. The error bars indicate standard deviations. The arrows indicate tumor regions.
doi:10.1371/journal.pone.0034463.g002
Figure 3. High-frequency ultrasound images of tumors ex vivo after extracting from mice treated with Dox and HerDox: Ultrasound
images were obtained of tumors extracted from (A) an untreated mouse, (B) a mouse treated with 0.004 mg/kg/day HerDox, or (C)
a mouse treated with 0.04 mg/kg/day Dox. (D) Echo signal intensities of A–C, respectively. The error bars reflect standard deviation. *: p,0.01.
doi:10.1371/journal.pone.0034463.g003
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Figure 4. TUNEL and H&E stained images of untreated, HerDox-treated, and Dox-treated tumors: (A) TUNEL images of untreated
tumors (left), HerDox-treated tumors (middle) (injection drug dosage: 0.004 mg/kg66 injections), Dox-treated tumors (right)
(injection drug dosage: 0.04 mg/kg66 injections) were acquired using confocal imaging (ex: 488 nm, em: 510–560 nm, and 106) of
tumor specimens. The arrows indicate the boundary between apoptotic and normal cells. Insets represent magnified images. (B) Average
fluorescence of the TUNEL images of untreated, Dox-treated, HerDox-treated tumor sections (*: p,0.01) (C) H&E images of untreated (left), HerGa-
treated tumors (middle), and Dox-treated tumors (right) were obtained using the Olympus microscope incorporating a CCD camera with a RGB filter
(106). The scale bar represents 200 mm. Arrows indicate nuclear shrinkage and fragmentation.
doi:10.1371/journal.pone.0034463.g004
Figure 5. Fluorescence intensity image of harvested tissue and in situ confocal fluorescence of tumors: (A) Fluorescence image (left-
panel; Ex: 532 nm; Em: 590±30 nm) of organs and tumors extracted from mice receiving HerDox (0.004 mg/kg/day; see Methods).
Confocal fluorescence images of the tumors extracted from HerDox-treated (A, right-panel), Dox-treated (B, right), and untreated mice (B, left) were
acquired at different z-depths (a total of thickness: 32 mm) with a step size of 2 mm. Maximum intensity z-projection of confocal fluorescence images
of HerDox-treated and untreated tumors was performed. HerDox and Dox fluorescence in (A) and (B) are indicated by a color shift toward 255 on the
scale bar in (A). The magnified image (A, right-panel) shows HerDox distribution in the tumor. Arrows indicate nuclei-localized fluorescence. (C) Mean
fluorescence intensity of HerDox-treated, Dox-treated and untreated tumor. The error bar indicates standard deviation. *: p,0.01.
doi:10.1371/journal.pone.0034463.g005
Multimodality Imaging for HerDox Assessment
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[Fig. 6B] shows HerDox localization in the tumor cells, in good
agreement with the classified image by the two reference spectral
signatures (red: 0.2?Dox+0.8?Autofl. and Green: Autofl.). Alto-
gether, these findings show that spectral classification can
discriminate doxorubicin fluorescence from autofluorescence, thus
verifying that the tumor fluorescence detected here is indeed due
to doxorubicin delivered by HerDox.
Discussion
We designed this study to take advantage of the specific
strengths of several complementary non-invasive imaging meth-
ods, used in a concerted (multimodal) way, in order to achieve
better quantification and understanding of targeted therapy-
relevant events in living animals, with ultimately translational
purposes. The imaging modalities utilized in this study have
provided multiple and complementary information in the
assessment and characterization of our nanoparticles. Through
these studies, we have observed that 1) high frequency ultrasound
imaging allows us to quantitatively assess nanoparticle efficacy at
micro scales, particularly tumor cell apoptosis, by resolving micro-
anatomy of tumor regions non-invasively. In contrast, standard
optical imaging technologies typically require contrast agents in
order to investigate tumor cell apoptosis in vivo [33]; 2) fluorescence
intensity and confocal imaging enables us to verify the tumor
targeting capacity of the nanoparticles at macro-to-micro scales; 3)
ratiometric spectral imaging allows us to discriminate between
Dox fluorescence and autofluorescence more quantitatively and
specifically, thus verifying the results obtained by using the
fluorescence intensity and confocal imaging ex vivo. In particular,
the methods, including confocal imaging and ratiometric spectral
imaging, complement one other: while confocal fluorescence
imaging provides insight into the local densities of Dox
distributions over cells by fluorescence difference in detail,
ratiometric spectral imaging, which typically is less sensitive to
local densities of fluorescent molecules, offers quantitative
discrimination between autofluorescence and Dox fluorescence.
In addition, confocal imaging offers more details than standard
fluorescence imaging of small animals or tissues, thus enabling
monitoring of Dox distributions over tumor cells at sub-micron
scales. Taken together, these imagaing modalities complement one
another when used in combination and provide multiple types of
information in the characterization of the nanoparticles during
preclinial asessement.
Previous studies have reported that cell death could be
monitored using high-frequency ultrasound imaging [29–32].
Those studies showed that the ultrasound echo intensity of tissues
was increased by cell apoptosis in vivo and ex vivo, and attributed
this increase in echo intensity to nuclear condensation and
fragmentation in apoptotic cells [29–32]. In the present study,
we could observe that the average intensity of the tumor increased
considerably after the third injection and increased significantly
over untreated tumors by the sixth injection of HerDox. In these
experiments, the ultrasound images obtained before HerDox and
Dox injection were utilized as negative controls. In addition, the in
vivo and in vitro results in Fig. 2C and 3 show that the untreated
tumors still exhibit lower echo signals than the HerDox and Dox-
treated tumors, thus indicating that the ultrasound echo signal
changes of untreated tumors within 6 days can be negligible
compared to the changes by HerDox and Dox treatment. In
agreement with these findings, the same tumor tissue yielded a
positive TUNEL signal, showing that apoptosis was induced by
drug treatment. The significant differences between the volumes of
drug-treated and untreated-tumors, which were measured using
calipers, were ascertained after monitoring tumor growth for up to
25 days following the drug administration in our previous studies
[26]. In contrast, high-frequency ultrasound imaging used here
enabled us to distinguish the echo intensity increase in the tumor
regions during tumor treatment, thus assessing the trajectory of
therapeutic efficacy much earlier. It is important to note that
HerDox and Dox are incapable of inherently causing any
significant increase of ultrasound echo signal because their sizes
(less than 40 nm) are significantly smaller than the ultrasound
wavelength.
Our previous studies have assessed the tumor targeting capacity
of HerDox in vivo by using fluorescence intensity imaging [26],
which has allowed us to understand how HerDox reaches tumors
and accumulates in them. In those studies, the dose required for
monitoring biodistribution of HerDox was nearly five-times the
therapeutic dose, as the therapeutic dose falls below the level of
Figure 6. Ratiometric spectral classification images of HerDox-treated tumors in situ: (A) Ratiometric spectral classification images
(middle and right-panel) of HerDox-treated tumors. Ratiometric spectral classification was performed using our previously developed
program. Green: autofluorescence (Autofl.), Red: 0.2 Dox+0.8 autofl., Cyan: 0.3 Dox+0.7 autofl., and Blue: 0.1 Dox+0.9 autofl.. The reference spectral
signatures used to generate the spectrally classified image are shown in the left-panel. (B) Spectral unmixed image. Scale bar: 80 mm.
doi:10.1371/journal.pone.0034463.g006
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detection for biodistribution and pharmacokinetic studies because
of the inherent weak fluorescence of Dox [26]. The multimodality
imaging system utilized here offers highly-sensitive fluorescence
intensity imaging, thus allowing us to detect sub-nano molar
cocentrations of Dox in vitro. Using the multimodality imaging in
the present study, we could observe tumor accumulation of
HerDox after multiple delivery at therapeutic doses in vivo.
Moreover, cellular accumulation could be observed and quanti-
tatively measured at the cellular and subcellular level using
confocal imaging (detection limitation: ,0.1 nM). In our prevous
in vitro stuides, we could observe that doxorubicin is localized in the
nucleus of HerDox and Dox-treated cells [26]. Here we could also
observe that Dox fluorescence could be found in the nuclei of
HerDox-treated cells. However, unlike HerDox-treated tumor
cells [Fig. 5(A)], we could not easily determine whether Dox is
localized in nuclei of the Dox treated tumor cells since the nuclei
localization could not be easily determined, likely due to cytoplasm
collapse [Fig. 5(B)]. While nuclear counter-staining, such as DAPI,
can be used to verify the localization of Dox in the tumor cells, this
was not performed because in situ confocal imaging of fresh, non-
processed, unstained tumors took place immediately after tumor
extraction. In general, non-viable cells exihibit stronger autofluo-
rescence than viable cells [34]. In the present study, we could
observe that the fluorescence emitted from HerDox-treated
tumors was nearly two-fold over the autofluorescence from
untreated tumors (Fig. 5C). The TUNEL assay [Fig. 4.(a)] verified
tumor cell apoptosis following HerDox treatment. In addition.
ratiometric spectral classification and spectral unmixing allowed us
to distinguish emissions due to HerDox fluorescence and
autofluorescence (Fig. 6). Based on these distinctions, our data
suggest that the increased fluorescence from the HerDox-treated
tumor is likely to result from both HerDox accumulation and cell
death rather than just the increased autofluorescence caused by
cell death alone. Hence, the combination of confocal and spectral
imaging allows discrimination between Dox fluorescence and
autofluorescence quantitatively. Taken together, our approch
shown here may also provide a better understanding of how
HerDox reaches tumors and achieves deposition of the drug
payload to the tumors.
In conclusion, the multimodal imaging approach used here,
which includes high-frequency ultrasound, fluorescence intensity,
confocal, and spectral imaging, has allowed us to assess the efficacy
of our novel tumor-targeted chemotherapeutic nanoparticle,
HerDox, thus providing an alternative method to the established
assessments of targeted therapeutic efficacy. The combination of
imaging modalities enables monitoring of tumor cell death during
HerDox treatment in vivo, in contrast to standard measurements of
tumor growth over time that delay such assessment until some
time after treatment. Overall, this may greatly shorten the time
required for assessing preclinical efficacy. Also, it enables
discerning and documenting of HerDox localization in tumors in
situ with high resolution, quantitatively and specifically. One may
envisage using this approach to screen a panel of new
nanotherapeutics in vivo in order to select one for more expanded
testing of therapeutic efficacy. Such an approach may enhance the
efficiency and accuracy of preclinical evaluation of new nano-
molecules, thus reducing time and cost for the translation of new
nanotherapeutics into the clinic as well as providing better cancer
treatments. Since the techniques described here, including
fluorescence intensity, confocal, and spectral imaging, are aimed
at fluorescence-based assessments, most therapeutic molecules
would require labeling with a fluorophore. This is not unusual,
and in fact, many researchers characterizing nanotherapeutic
particles in vivo have attached fluorophores to their particles to
visualize localization in vivo. Whether the molecules of interest are
inherently fluorescent, such as the HerDox molecule described
here, or labeled with a fluorophore, the multimodality imaging
method described here can provide a powerful approach for
characterizing nanoparticle activities in vivo in preclinical studies.
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